CoChat

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Open access
Garske-Román, Ulrike, Sandström, Mattias, Fröss Baron, Katarzyna, Lundin, Lars, Hellman, Per, Welin, Staffan, Johansson, Silvia, Khan, Tanweera, Lundqvist, Hans, Eriksson, Barbro, Sundin, Anders, Granberg, Dan · 2018 · European Journal of Nuclear Medicine and Molecular Imaging

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

PURPOSE: Peptide receptor radionuclide therapy in patients with neuroendocrine tumours has yielded promising results. This prospective study investigated the feasibility of dosimetry of the kidneys and bone marrow during therapy and its impact on efficacy and outcome. METHODS: Lu-DOTA-octreotate with co-infusion of a mixed amino acid solution, and cycles were repeated until the absorbed dose to the kidneys reached 23 Gy or there were other reasons for stopping therapy. The Ki-67 index was ≤2% in 47 patients (23.5%), 3-20% in 121 (60.5%) and >20% in 16 (8%). RESULTS: In 123 patients (61.5%) the absorbed dose to the kidneys reached 23 Gy with three to nine cycles during first-line therapy; in no patient was a dose to the bone marrow of 2 Gy reached. The best responses (according to RECIST 1.1) were a complete response (CR) in 1 patient (0.5%), a partial response (PR) in 47 (23.5%), stable disease (SD) in 135 (67.5%) and progressive disease (PD) in 7 (3.5%). Median progression-free survival was 27 months (95% CI 22-30 months) in all patients, 33 months in those in whom the absorbed dose to the kidneys reached 23 Gy and 15 months in those in whom it did not. Median overall survival (OS) was 43 months (95% CI 39-53 months) in all patients, 54 months in those in whom the absorbed dose to the kidneys reached 23 Gy and 25 months in those in whom it did not. Median OS was 60 months in patients with a best response of PR or CR, 42 months in those with SD and 16 months in those with PD. Three patients (1.5%) developed acute leukaemia, 1 patient (0.5%) chronic leukaemia (unconfirmed) and 30 patients (15%) grade 3 or 4 bone marrow toxicity. Eight patients (4%) developed grade 2 kidney toxicity and one patient (0.5%) grade 4 kidney toxicity. CONCLUSIONS: Lu-DOTA-octreotate is feasible. Patients in whom the absorbed dose to the kidneys reached 23 Gy had a longer OS than those in whom it did not. Patients with CR/PR had a longer OS than those with SD. Bone marrow dosimetry did not predict toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00259-018-3945-z

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Patients with small intestinal NET (SI NET) show lower objective response rates according to RECIST 1.1 than patients with all other types of tumours (Non-SI NET). The proportions of patients in the respective groups with complete and partial responses (CR/PR), stable disease (SD) and progressive disease (PD) or data not available for radiological evaluation (NA) are indicated. Shaded areas Proportions of patients in whom the absorbed dose to the kidneys reached 23 Gy (numbers of patients are given in Table 4)
Fig. 1 Patients with small intestinal NET (SI NET) show lower objective response rates according to RECIST 1.1 than patients with all other types of tumours (Non-SI NET). The proportions of patients in the respective groups with complete and partial responses (CR/PR), stable disease (SD) and progressive disease (PD) or data not available for radiological evaluation (NA) are indicated. Shaded areas Proportions of patients in whom the absorbed dose to the kidneys reached 23 Gy (numbers of patients are given in Table 4)CC BY · PubMed Central
Fig. 2 Progression-free survival (PFS; a, c, e) and overall survival (OS; b, d, f) from the start of therapy with 177Lu-DOTA-octreotate in relation to absorbed dose to the kidneys, best morphological response according to RECIST 1.1 and proliferation rate (Ki-67 index). a, b PFS (a) and OS (b) in 123 of 124 patients in whom the absorbed dose to the kidneys reached 23 Gy (blue line) and in 76 patients in whom it did not (red line); grey line combined data. c, d PFS (c) and OS (d) in relation to best response according to RECIST 1.1: progressive disease (PD, red line), median PFS 6 months (95% CI 3–9 months), median OS 15.5 months (95% CI 5–36 months); stable disease (SD, green line), median PFS 28 months (95% CI 21–31 months), OS 42 months (95% CI 34–51.5 months); partial response/complete response (PR&CR, blue line), median PFS 31 months (95% CI 23–35 months), OS 60 months (95% CI 43 months, upper limit not reached, NR). e, f PFS (e) and OS (f) in relation to proliferation rate (Ki-67 index): grade 1, Ki-67 index ≤2% (red line), PFS 33 months (95% CI 24–41 months), OS 48 months (95% CI 40 months, NR); grade 2, Ki-67 index 3–20% (green line), median PFS 23 months (95% CI 19–28 months), median OS 41 months (95% CI 32.5–60 months); grade 3, Ki-67 index >20% (blue line), median PFS 14 months (95% CI 10–21 months), median OS 31 months (95% CI 19–39 months)
Fig. 2 Progression-free survival (PFS; a, c, e) and overall survival (OS; b, d, f) from the start of therapy with 177Lu-DOTA-octreotate in relation to absorbed dose to the kidneys, best morphological response according to RECIST 1.1 and proliferation rate (Ki-67 index). a, b PFS (a) and OS (b) in 123 of 124 patients in whom the absorbed dose to the kidneys reached 23 Gy (blue line) and in 76 patients in whom it did not (red line); grey line combined data. c, d PFS (c) and OS (d) in relation to best response according to RECIST 1.1: progressive disease (PD, red line), median PFS 6 months (95% CI 3–9 months), median OS 15.5 months (95% CI 5–36 months); stable disease (SD, green line), median PFS 28 months (95% CI 21–31 months), OS 42 months (95% CI 34–51.5 months); partial response/complete response (PR&CR, blue line), median PFS 31 months (95% CI 23–35 months), OS 60 months (95% CI 43 months, upper limit not reached, NR). e, f PFS (e) and OS (f) in relation to proliferation rate (Ki-67 index): grade 1, Ki-67 index ≤2% (red line), PFS 33 months (95% CI 24–41 months), OS 48 months (95% CI 40 months, NR); grade 2, Ki-67 index 3–20% (green line), median PFS 23 months (95% CI 19–28 months), median OS 41 months (95% CI 32.5–60 months); grade 3, Ki-67 index >20% (blue line), median PFS 14 months (95% CI 10–21 months), median OS 31 months (95% CI 19–39 months)CC BY · PubMed Central
Fig. 3 Progression-free survival (PFS, a) and overall survival (OS, b) in 154 patients who stopped therapy for reasons other than progression or clinical deterioration. In 114 patients in whom the absorbed dose to the kidneys reached 23 Gy, PFS was 34 months (95% CI 31–37 months) and OS was 60 months (95% CI 47 months, NR). In 39 of 40 patients in whom a dose of 23 Gy was not reached, PFS was 20 months (95% CI 16–28 months) and OS was 33 months (95% CI 29–48 months; p < 0.0001 for PFS, p = 0.0004 for OS); grey line combined data, red symbols patient died, blue symbols patient alive, triangles patient received salvage therapy
Fig. 3 Progression-free survival (PFS, a) and overall survival (OS, b) in 154 patients who stopped therapy for reasons other than progression or clinical deterioration. In 114 patients in whom the absorbed dose to the kidneys reached 23 Gy, PFS was 34 months (95% CI 31–37 months) and OS was 60 months (95% CI 47 months, NR). In 39 of 40 patients in whom a dose of 23 Gy was not reached, PFS was 20 months (95% CI 16–28 months) and OS was 33 months (95% CI 29–48 months; p < 0.0001 for PFS, p = 0.0004 for OS); grey line combined data, red symbols patient died, blue symbols patient alive, triangles patient received salvage therapyCC BY · PubMed Central
Fig. 4 Progression-free survival (PFS, a) and overall survival (OS, b) in all 50 patients who received exactly four cycles of 177Lu-DOTA-octreotate. In 33 patients in whom the absorbed dose to the kidneys reached 23 Gy, PFS was 35 months (95% CI 23 months, NR) and OS was 60 months (95% CI 47 months, NR). In 17 patients in whom a dose of 23 Gy was not reached, PFS was 16 months (95% CI 9–18 months) and OS was 19 months (95% CI 15 months, NR; p = 0.0003 for PFS, p = 0.0006 for OS, log-rank test; grey line combined data, red symbols patient died, blue symbols patient alive, triangles patient received salvage therapy
Fig. 4 Progression-free survival (PFS, a) and overall survival (OS, b) in all 50 patients who received exactly four cycles of 177Lu-DOTA-octreotate. In 33 patients in whom the absorbed dose to the kidneys reached 23 Gy, PFS was 35 months (95% CI 23 months, NR) and OS was 60 months (95% CI 47 months, NR). In 17 patients in whom a dose of 23 Gy was not reached, PFS was 16 months (95% CI 9–18 months) and OS was 19 months (95% CI 15 months, NR; p = 0.0003 for PFS, p = 0.0006 for OS, log-rank test; grey line combined data, red symbols patient died, blue symbols patient alive, triangles patient received salvage therapyCC BY · PubMed Central
Fig. 5 A 43-year-old female patient with VIPoma. a Cropped whole-body scans (WBS) obtained on day 1 after treatment with 177Lu-DOTA-octreotate during initial treatment (cycles 1–5) and salvage therapy. Note the change in size and uptake intensity of the different tumours throughout therapy. Imaging at the time of salvage therapy after progression shows new uptake in the skeleton, but the total tumour burden is still lower than at the start of therapy. b Absorbed organ doses (in absolute values and in relation to administered activity) to the kidneys, liver parenchyma and spleen , and to three representative tumour lesions with homogeneous uptake, measured in the same area during each cycle of initial treatment and during salvage therapy. c Layout of the dosimetry programme (implemented on a Hermes platform, Nuclear Diagnostics International AB). The hair cross is positioned on the metastatic uptake in the liver, the small circle corresponds to a 4-cm3 volume of interest (VOI). For tumour and solid organ dosimetry, calculations of absorbed doses were based on volume concentrations in small VOIs drawn on SPECT/CT images at three time-points (24 h, 4 days and 7 days after infusion). In this patient, three SPECT/CT scans were acquired during cycles 1, 2 and 4 and cycle 1 of salvage therapy. For the other cycles, one SPECT/CT scan was acquired at 24 h and the absorbed dose was calculated assuming unchanged kinetics from the previous therapy
Fig. 5 A 43-year-old female patient with VIPoma. a Cropped whole-body scans (WBS) obtained on day 1 after treatment with 177Lu-DOTA-octreotate during initial treatment (cycles 1–5) and salvage therapy. Note the change in size and uptake intensity of the different tumours throughout therapy. Imaging at the time of salvage therapy after progression shows new uptake in the skeleton, but the total tumour burden is still lower than at the start of therapy. b Absorbed organ doses (in absolute values and in relation to administered activity) to the kidneys, liver parenchyma and spleen , and to three representative tumour lesions with homogeneous uptake, measured in the same area during each cycle of initial treatment and during salvage therapy. c Layout of the dosimetry programme (implemented on a Hermes platform, Nuclear Diagnostics International AB). The hair cross is positioned on the metastatic uptake in the liver, the small circle corresponds to a 4-cm3 volume of interest (VOI). For tumour and solid organ dosimetry, calculations of absorbed doses were based on volume concentrations in small VOIs drawn on SPECT/CT images at three time-points (24 h, 4 days and 7 days after infusion). In this patient, three SPECT/CT scans were acquired during cycles 1, 2 and 4 and cycle 1 of salvage therapy. For the other cycles, one SPECT/CT scan was acquired at 24 h and the absorbed dose was calculated assuming unchanged kinetics from the previous therapyCC BY · PubMed Central
Fig. 6 Absorbed doses to the kidneys in the first cycle (a, b) and the last cycle in each patient (cycles 2 to 10; c, d) during initial treatment. Throughout therapy, doses could decrease or increase. Shaded bars indicate patients who received an absorbed dose of 3 to 4 Gy to their right kidney in the first cycle (a). In their last cycle, absorbed doses to the right kidney varied between 2 and 6 Gy (c). Dose distributions in the left kidneys of the same patients correspond to shaded areas in b and d
Fig. 6 Absorbed doses to the kidneys in the first cycle (a, b) and the last cycle in each patient (cycles 2 to 10; c, d) during initial treatment. Throughout therapy, doses could decrease or increase. Shaded bars indicate patients who received an absorbed dose of 3 to 4 Gy to their right kidney in the first cycle (a). In their last cycle, absorbed doses to the right kidney varied between 2 and 6 Gy (c). Dose distributions in the left kidneys of the same patients correspond to shaded areas in b and dCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 266

Metadata

Authors
Garske-Román, U., Sandström, M., Fröss Baron, K., Lundin, L., Hellman, P., Welin, S., Johansson, S., Khan, T., Lundqvist, H., Eriksson, B., Sundin, A., & Granberg, D.
Affiliations
Uppsala University (SE)
Venue
European Journal of Nuclear Medicine and Molecular Imaging
Published
2018-03-01
Volume
45
Issue
6
Pages
970-988
ISSN
  • 1619-7070 (ISSN-L)
  • 1619-7089
OpenAlex
W2789923927
Cited by
254
References
44
Citations by year
2026: 20 · 2025: 18 · 2024: 30 · 2023: 36 · 2022: 41 · 2021: 44 · 2020: 33 · 2019: 21 · 2018: 10
FWCI
21.08
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
Funders
Uppsala University
Topics
  • Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
peptide receptor radionuclide therapy, neuroendocrine tumors, metastatic neuroendocrine tumors, kidney dosimetry, bone marrow dosimetry, absorbed dose, treatment toxicity, progression-free survival, overall survival, acute leukemia, nephrotoxicity, myelosuppression, Ki-67 proliferation index
MeSH terms
Adolescent, Adult, Aged, Dose-Response Relationship, Radiation, Female, Humans, Male, Middle Aged, Organometallic Compounds, Prospective Studies, Octreotide, Receptors, Peptide, Neuroendocrine Tumors, Young Adult, Coordination Complexes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. https://app.cochat.ai/papers/10.1007/s00259-018-3945-z
The paper
Garske-Román, U., Sandström, M., Fröss Baron, K., Lundin, L., Hellman, P., Welin, S., Johansson, S., Khan, T., Lundqvist, H., Eriksson, B., Sundin, A., & Granberg, D. (2018). Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-018-3945-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.